Y-mAbs Therapeutics, Inc.’s Post

You may remember some of the key themes we shared ahead of #ASCO24. Post-congress, our experts are reflecting back on those themes and summarizing the key insights and takeaways on these modalities from ASCO 2024. Read more & get in touch: https://lnkd.in/eHCmAX36 #CancerResearch #ADCs #RadioPharmaceuticals #Bispecifics

Exploring the Impact of Radiopharmaceutical Manufacturing At AtomVie Global Radiopharma (AtomVie), we are at the forefront of producing high-quality radiopharmaceuticals that are transforming patient lives. Our services include cutting-edge processes such as analytical method development, tech transfer, qualification, and validation, leading to the clinical and commercial supply of radiopharmaceuticals and their global distribution. These services enable us to manufacture innovative agents for our clients under GMP standards, which can be applied across various fields, such as oncology, neurology, cardiology, and inflammation. Take a look at the transformative applications of radiopharmaceuticals in the slide below. Have you encountered any other new applications? We invite you to share your insights in the comments below and check out our website https://lnkd.in/eRfgP6FK to learn more about our services. Together, let's continue our mission of revolutionizing patient care with high-quality radiopharmaceuticals, one dose at a time. #AtomVieGlobalRadiopharma #radiopharmaceuticals #nuclearmedicine #manufacturingexcellence #patientoutcomes

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) is making significant strides in developing tecarfarin, a late-stage new generation vitamin K antagonist aiming to address unmet chronic anticoagulation needs in cardiovascular care.    Key Highlights:   Launched a collaborative effort with Abbott to advance tecarfarin for patients with left ventricular assist devices (LVADs). The Abbott HeartMate 3™ is the only LVAD available in the U.S.   Received FDA Orphan Drug Designation in April 2024 for the prevention of blood clots and strokes in patients with LVADs and other implanted cardiac devices.   Dr. Mandeep Mehra presented ARIES-HM3 secondary analysis at the International Society for Heart & Lung Transplantation Annual Meeting and commented that, "Tecarfarin could potentially be an important therapy for patients with LVADs."   Progressing towards Phase 3 trials to evaluate tecarfarin’s effectiveness and superiority to warfarin in LVAD patients.   We are focused on delivering for patients and investors. We remain dedicated to bringing better anticoagulation solutions to those who need them most.    For more information, visit: www.cadrenal.com   https://lnkd.in/gmun2iHW  #CadrenalTherapeutics Cadrenal Therapeutics, Inc. (Nasdaq: CVKD)

Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab Is Standard of Care for High-Risk Early-Stage TNBC: Overall survival results from the phase 3 KEYNOTE-522 study provide evidence of improved long-term outcomes from this pembrolizumab-based regimen. #finance #pharmacy #lifesciences

Thoughts on this? >> Ipsen pays Day One $111M upfront for ex-US rights to pediatric brain tumor drug >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #pharma #healthcare #pharmaceutical #biotech

Join my colleagues, Jay Grisolano, Stephanie Hawthorne, and I, along with UCLA's Deborah Wong, and BiotechTV's Brad Loncar, for this year's ASCO preview webinar. We'll discuss anticipated data readouts and the impact on clinical practice, and the commercial implications for pharma and the financial sector. Register below! #ASCO24 #oncology

GenFleet Therapeutics Fulzerasib has emerged as a strong contender in the treatment of KRAS G12C-mutated NSCLC, surpassing the efficacy of sotorasib and adagrasib. Its combination with cetuximab has shown exceptional promise, leading to plans for a Phase III trial. This highlights the potential for fulzerasib to become a key player in first-line therapy, pending further validation. Discover Expert Insights and In-Depth Analysis with DelveInsight Business Research LLP's Exclusive American Society of Clinical Oncology (ASCO) 2024 Coverage! https://lnkd.in/gQRnmPZ3 #ASCO24 #CancerTreatment #ASCO2024 #LungCancer #NSCLC #mCRPC #PharmaInnovation #MedicalResearch #OncologyAdvancements #ClinicalOncology #Pharmaceuticals #HealthcareConference #CancerResearch #ClinicalPractice #MedicalBreakthroughs #CancerCare #PharmaLeaders

DelveInsight's comment: Fulzerasib emerges as a game-changer for KRAS G12C-mutated NSCLC with promising preliminary efficacy and an excellent safety profile in Phase II KROCUS Study!

Orca Biosystems’s TRGFT-201, also known as Orca-T, is the next product which could make it to market. A Phase III trial investigating the candidate is due to meet primary completion in April 2024. Orca-T is an engineered allogeneic peripheral blood product that comprises purified donor-derived regulatory T-cell plus CD34 and haematopoietic progenitor cells. The Precision-T trial (NCT05316701) is investigating patients with advanced haematologic malignancies undergoing allogeneic hematopoietic cell transplantation with either TRGFT-201 with additional infusion of conventional T-cells and regulatory T-cells, or standard-of-care allogeneic graft. #celltherapies #gvhd #innovation #patient #drugdevelopment #pharma

At #ESMO2024 Congress, GSK and iTeos presented promising P2 results on their TIGIT inhibitor, belrestotug, combined with GSK's PD-1 inhibitor, Jemperli, for PD-L1-positive NSCLC. The IO/IO combo significantly boosted the ORR compared to Jemperli alone, providing a ray of positive hope for aTIGIT therapies. sAEs, irAEs and high discontinuation rates in the combo arm, however, pose notable challenges. #CancerResearch #MedicalInnovation